Wells Fargo raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes’ (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Amends Agreement with Alkermes
- Alkermes increases offer to acquire Avadel Pharmaceuticals to $22.50 per share
- Avadel Pharmaceuticals put volume heavy and directionally bearish
- Avadel Pharmaceuticals Receives Superior Proposal from Lundbeck
- Avadel board declares Lundbeck proposal superior to Alkermes offer